doi: http://dx.doi.org/10.4314/jmbs.v5i2.5

ORIGINAL ARTICLE

Dengue virus exposure among blood donors in Ghana

P. W. Narkwa¹, M. Mutocheluh¹, T. B. Kwofie¹, M. Owusu^{2,3}, A. Annan³, I. Ali⁴ and J. K. Boamah⁴

Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; ²Department of Clinical Microbiology, Komfo Anokye Teaching Hospital, Kumasi, Ghana; ³Kumasi Centre for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; ⁴Malaria Research Unit, Kumasi Centre for Collaborative Research Agogo, Ghana

Dengue is an urban arbovirus whose aetiologic agent is the flavivirus with four distinct antigen serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) that is transmitted to humans through the bite of the mosquito Aedes aegypti. Ghana is endemic for Aedes aegypti mosquitoes and probably dengue viruses. Due to limited data on dengue virus exposure among Ghanaians, we surveyed 188 healthy adult blood donors for the presence of IgG and IgM antibodies to the four serotypes of dengue. Five milliliters of peripheral blood from the blood donors were collected in plain tubes. Serum was then obtained and ELISA tests were employed to detect both dengue virus total antibodies and IgM. The samples were further tested for dengue virus RNA using RT-PCR. Dengue virus IgG was positive for 43.6% of all the 188 blood donor samples tested but all donors were negative for anti-dengue IgM antibody and dengue virus RNA. The rate of dengue virus total antibody exposure did not differ statistically between urban and rural districts. This study shows for the first time that some regions of Ghana are hyperendemic for dengue virus infection but suggests blood for transfusion is invariably dengue virus free. This report has provided a baseline data that will inform wider discussions about the impact of this dengue fever and also guide policy makers to develop effective and affordable early warning and outbreak response systems for Ghana. Journal of Medical and Biomedical Sciences (2016) 5(2), 30-35

Keywords: ELISA; RT-PCR; Immunoglobulin, Dengue virus RNA, blood transfusion, Ghana

INTRODUCTION

Dengue fever, dengue haemorrhagic fever and dengue shock syndrome are dangerous and debilitating diseases caused by dengue virus (serotypes 1-4). The World Health Organization (WHO) estimates about 2.5 billion people live in regions potentially at risk of dengue infection. About 100 million cases of dengue fever and more than 500,000 cases of dengue hemorrhagic fever occur on yearly basis while approximately 25,000 die from dengue related clinical manifestations (WHO, 2012).

Primary dengue infection has similar clinical picture

is transmitted by mosquitoes (Aedes). Flaviviruses are small, lipid-enveloped, positive-stranded RNA viruses (Gubler, 2002). Dengue virus infection in humans is often inapparent (Endy et al., 2011; Simmons et al., 2012) but can lead to a wide range of clinical manifestations, from mild fever to potentially fatal dengue shock syndrome (WHO, 2009). The viremic phase of dengue infection lasts 4–8

as malaria. In sub-Saharan Africa, health resource

constraints result in the majority of febrile illnesses

being presumptively treated as malaria, although

growing evidence suggests that in some cases, ma-

laria may only be responsible for a minority of ill-

Dengue virus belongs to the family Flaviviridae and

days (Gubler et al., 1981) and precedes the onset of

symptoms in persons with clinical disease but most

Correspondence: Mohamed Mutocheluh, Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Email: mmutocheluh.chs@knust.edu.gh or mutocheluh@gmail.com

nesses.

infections are subclinical (Burke et al., 1988). Plasma viral RNA levels range from 106 to 109 copies/mL, and blood collected during this phase may be infective when transfused into susceptible hosts (Sudiro et al., 2001). Dengue has been reported in many African countries and the average mortality rate is about 5%. Although dengue infection or outbreak has not been confirmed in Ghana, it has been detected in Côte d'Ivoire and Burkina Faso, which share common borders with Ghana (WHO, 1995).

MATERIALS AND METHODS

The study sites

A cross-sectional seroprevalence study was conducted at the blood transfusion centres at three different sites (hospitals) namely Agogo Presbyterian Hospital (Agogo), Techiman Holy Family Hospital (Techiman) and the Komfo Anokye Teaching Hospital (KATH) in Kumasi between February 2013 and December 2015. The Agogo Presbyterian Hospital is a referral hospital for the Asante Akim North, Central and South Districts of Ashanti Region of Ghana whereas the Techiman Holy Family Hospital is the main referral hospital within the Techiman district of the Brong Ahafo Region of Ghana. The Komfo Anokye Teaching Hospital (KATH) is located in the city of Kumasi. KATH is Ghana's second tertiary hospital.

Ethical approval

Prior to the study, ethics approval was sought from the KNUST School of Medical Science/KATH Committee on Human Research Publications and Ethics (CHRPE). In all, 188 prospective blood donors (age range: 17-58 years) were enrolled. The participation of the respondents was voluntary and informed consent was obtained from each of them.

Sample collection and storage

All subjects who visited the laboratories of the above stated blood transfusion centres to donate blood were approached and examined with the following inclusion criteria for the study: age between 16 to 60 years, least weight of 50 kg, haemoglobin level of at least 12.5 g/dl, blood pressure <140/90 mmHg and pulse < 100 BPM. All individuals who

passed the above stated inclusion criteria and were considered physically fit to donate blood were enrolled into the study. All those who did not meet these criteria were excluded from the study.

Five millilitres pre-donation venous blood specimens were collected from each prospective blood donor under strict aseptic conditions for screening. After the routine screening of the blood donors' serum samples for HIV, HBsAg, VDRL, Hepatitis C virus, the remaining serum samples of all the study participants were stored at -20 °C. The frozen plasma samples were later transported to the virus research laboratory of the Department of Clinical Microbiology of the School of Medical Sciences of Kwame Nkrumah University of Science and Technology where this study was performed.

Testing of sera for DENV-specific IgM/IgG antibodies

The samples were allowed to thaw at room temperature and then tested for dengue virus specific antibodies (IgM/IgG) using AccuDiagTM Dengue IgM/IgG ELISA kit (Diagnostic Automation/Cortez Diagnostic, Inc. Calabasas, California 91302, USA) following the manufacturer's instructions. The microwells are coated with purified dengue virus antigen from Vero cell cultured type 1-4 dengue. In the presence of human sera any antibody present will bind to the wells; results are obtained following the completion of the test procedure. Donors were considered positive against dengue virus when the ELISA result was defined as having an index value greater than 1.1. Both the sensitivity and specificity of the kit were 100% according to the manufactur-

Testing of sera for DENV-specific IgM antibodies

Dengue virus (DENV) DetectTM IgM capture ELI-SA (InBios, USA) was used in testing for the presence of IgM antibodies in human serum to Dengue derived recombinant antigens (DENRA) following the manufacturer's instruction. Prior to the test, the components of the kits were pre-warmed to room temperature. A 1: 100 dilutions of the samples and the controls (positive and negative controls) were

made using the DENV Sample Dilution Buffer. The optical densities of the wells were measured at 450 nm using iMark Microplate Reader (Bio-Rad, USA). The Immune Status Ratios (ISR) of the negative and the positive controls which were calculated as the ratio between the averaged optical density (OD) of dengue recombinant antigen (DENRA) to average OD of normal cell antigen (NCA) were used in the determining the validity of the assay. The ISR of the unknown samples were also calculated as the ratio between the averaged OD of DENRA to average OD of NCA. An unknown sample with ISR ≤ 1.65 was considered as negative for Dengue IgM. An unknown sample with ISR of 1.65<ISR<2.84 was considered as equivocal meaning the test must be repeated in duplicate and the average ISR evaluated. Samples that remained equivocal after repeated testing were considered as negative for Dengue IgM. Samples with ISR \geq 2.84 were considered as positive for Dengue IgM antibodies.

Real-time PCR testing for Dengue Viruses

The RNA of all samples that were IgG and IgM positive were extracted using Qiagen Viral RNA Minikit (Qiagen, Germany). Real-time PCR was performed on the extracts to identify dengue virus: DENV1, DENV2, DENV3, and DENV4. The reactions were carried out in a 25 µl reaction mixture containing 5 µl of RNA template, 2x Reaction Mix containing

3.2mM MgSO₄, 1 µl of 1 mg/ml Bovine Serum Albumin, 50 mM MgSO₄, 0.5 µl forward primer, 1 µl of reverse primer, 0.5 µl of probe and 1 µl of superscript III platinum-Taq Enzyme Mix (Invitrogen). Thermocycling parameters were as follows: reverse transcription at 45 °C for 30 min, denaturation at 95 °C for 5 min, followed by 45 cycles at 95 °C for 3 seconds and annealing at 57 °C for 35 seconds. The sequences of probes and primers are described by Drosten et al., 2002 (Drosten et al., 2002).

Data analysis

All data were entered using microsoft excel spreadsheet. A simple proportion of dengue positive vs negative were assessed by means of Students *t*-test.

RESULTS

Of the total 188 blood serum samples tested 82 (43.6%) were positive for dengue virus IgG whereas 106 (56.4%) tested negative. Also, all 188 blood serum samples tested negative for anti-dengue virus IgM and the dengue virus RNA.

The overall prevalence rate of dengue infection was thus 43.6%. However, the prevalence for Agogo, Techiman and Kumasi were 37.8%, 37.8% and 24.4% respectively (Table 1). The mean age of the entire study population was 28.8 years (age range:

TABLE 1. Sociodemographic of 188 healthy adult blood donor stratified by three study sites in Ghana: Kumasi, Agogo and Techiman

Characteristic	Total population	IgM/IgG positive	IgM/IgG Negative	P-value
	N = 188	N = 82	N = 106	
Gender				
Male	170 (90.4)	79 (96.3)	91 (85.8)	0.024
Female	18 (9.6)	3 (3.7)	15 (14.2)	
Age group				
17-19	29 (15.4)	12 (14.6)	17 (16)	
20-29	88 (46.8)	43 (52.4)	45 (42.5)	0.484
30-39	45(23.9)	19 (23.2)	26(24.5)	0.943
40-49	18(9.6)	6(7.3)	12 (11.3)	0.582
50-58	8(4.3)	2 (2.4)	6 (5.7)	0.404
Study site	, ,	` ,	, ,	
Agogo	64 (34.0)	31 (37.8)	33 (31.1)	
Techiman	62 (33.0)	31 (37.8)	31 (29.2)	0.861
Kumasi	62 (33.0)	20 (24.4)	42 (39.6)	0.066

17 to 58 years) whereas that of Agogo, Techiman and Kumasi were 29.9, 30.5 and 26.7 years respectively.

The predominant males (90.4%) among the study population had a higher dengue seroprevalence of 96.3%, compared with 3.7%, observed among the minority females (9.6%), (Table 1). Majority of the study donors who tested positive for dengue antibodies fell into the 20-29 age range. Donors within the oldest group (≥50 years) not only were a minority but also had the lowest dengue seroprevalence as shown in Table 1.

DISCUSSION

To the best of our knowledge this is the first study that provides evidence on circulation of dengue virus antibodies among blood donors in the Ashanti and Brong Ahafo regions of Ghana where outbreaks of dengue fever have never been documented. The absence of anti-dengue virus IgM in the current study suggests the blood donors were not actively infected with dengue virus. The absence of anti-dengue virus IgM antibodies could also be attributed to the stringent pre-blood donation assessments to ensure that only healthy and qualified blood donors actually donate blood in Ghanaian hospitals.

The current study found dengue virus exposure of 43.6% among blood donors in all three-study sites. Although Kumasi is a city or an urban centre there was no statistical difference in the virus exposure compared to both Agogo and Techiman, which are comparatively smaller towns. Urban dwellers are normally less exposed to mosquitoes compared to people leaving in smaller districts but recent reports show that a major drive contributing to the spread of dengue virus to urban centres around the world is modern transportation and travel to endemic areas (Wilder-Smith and Schwartz, 2005; Gubler, 2006; Wilder-Smith and Gubler, 2008; Gubler, 2011).

The results of the current study are in line with a similar study in Tanzania that showed a high dengue virus seroprevalence of 50.6% (Vairo *et al.*, 2014) and another study in Nigeria that reported 45% for DENV-2 infection (Fagbami *et al.*, 1977). Also, den-

gue virus seroprevalence rate in the adult population in Singapore was 45% (Wilder-Smith *et al.*, 2004) in line with findings from the current study. However, the results from the current study are in sharp contrast to a report by Pascal Richard and colleagues who studied the seroprevalence of antidengue virus IgG among 783 adult blood donors from the French Carribbean islands of Guardeloupe and Martinique and reported that 90.7% of the samples tested positive for dengue antibodies (Azou *et al.*, 2015).

Geographically Ghana falls within the dengue endemic countries (Bhatt et al., 2013) but there are no official records on dengue virus outbreak or diagnosed infections yet. Appawu et al., reported 56% of households in each study site as positive for Aedes larvae in a survey to estimate larval indices and man-vector contacts of potential vectors of viral haemorrhagic fevers such as dengue and yellow fever (Appawu et al., 2006). The high population size of Aedes in some Ghanaian households could be responsible for the high seroprevalence rate of dengue reported in this study.

Age group 20 - 39 was the most exposed to dengue virus infection consistent with a report by Vairo's group that showed majority of the blood donors exposed to dengue were aged 26 - 35 (Vairo et al., 2014). Although the exact age at which each blood donor was infected cannot be determined the results suggest prolonged exposure to the infection was a risk factor. The few limitations to this study were: firstly, the samples size was less representative of the general population and could have affected the results, either by underestimating or overestimating the inferred prevalence. Secondly, the vast majority of the study participants were males. As expected, males dominate the blood donor population worldwide and particularly in Africa where some socio-cultural and religious believes preclude females from donating blood. Thirdly, the plaque reduction neutralisation test (PRNT) should have been used as the confirmatory test for anti-DENV IgG-positive samples to determine antibody and serotype specificity (Roehrig et al., 2008). PRNT was not available in Ghana at the time of this study.

CONCLUSION

Taken together, the current study suggests blood for transfusion in Ghana are dengue virus free although many Ghanaians are exposed to dengue virus infections. It is anticipated that these findings would provide a starting point for a wider discussion about the impact of dengue infections and will help to guide policy makers develop effective and affordable early warning and outbreak response systems for Ghana.

ACKNOWLEDGEMENT

This work was supported with project funds from the Leverhulme-Royal Society Africa Award II grant. We thank all the study subjects and the hospital staff who assisted with sample collection. We are grateful to Dr Shirley Owusu-Ofori for granting permission to the student on this project to collect samples from the KATH blood bank.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

- Appawu M., Dadzie S., Abdul H., Asmah H., Boakye D., Wilson M. and Ofori-Adjei D. (2006) Survellance of viral haemorrhagic fevers in Ghana: Entomological assessment of the risk of transmission in the northern regions. *Ghana Medical Journal* 40:137-141.
- Azou M.L., Jean-Marie J., Bessaud M., Cabie A., Ce'saire R., de Lamballerie X., Courbil R. and Richard P. (2015) Dengue Seroprevalence in the French West Indies: A Prospective Study in Adult Blood Donors. *Am. J. Trop. Med. Hyg* 92(6); 1137-1140.
- Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L. et al (2013) The global distribution and burden of dengue *Nature* DOI:10.1038/nature12060.
- Burke D.S., Nisalak A., Johnson D.E. and Scott R.M. (1988) A prospective study of dengue infections in Bangkok. *Am J Trop Med Hyg* 38:172–80.
- Drosten C., Gottig S., Schilling S., Asper M., Pan-

- ning M., Schmitz H. and Gunther S. (2002) Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR *Journal of clinical microbiology* 40:2323-2330.
- Endy T.P., Anderson K. B., Nisalak A., Yoon I-K., Green S., Rothman A.L., Thomas S.J., Jarman R.G., Libraty D.H., Gibbons R.V. (2011) Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. *PLoS Negl. Trop. Dis* 5, e975.
- Fagbami A.H., Monath T.P. and Fabiyi A. (1977) Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. *Trans* R Soc Trop Med Hyg 71:60–5
- Gubler D.J. (2002) The global emergence/ resurgence of arboviral diseases as public health problems *Arch Med Res* 33:330–42
- Gubler D.J. (2006) Dengue/dengue haemorrhagic fever: history and current status. In New treatment strategies for dengue and other flaviviral diseases: Novartis Foundation Symposium 277. Edited by Bock G, Goode J. Chichester, UK: John Wiley & Sons, Ltd; 2006:3–22.
- Gubler D.J. (2011) Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. *Trop Med Health* 39(Suppl 4):3–11.
- Gubler D.J., Suharyono W., Tan R., Abidin M. and Sie A. (1981) Viraemia in patients with naturally acquired dengue infection *Bull World Health Organ* 59:623–30.
- Roehrig J.T., Hombach J. and Barrett A.D. (2008) Guidelines for plaque- reduction neutralization testing of human antibodies to dengue viruses. *Viral Immunol* 21:123–132.
- Simmons C.P., Farrar J.J., van Vinh Chau N. and Wills B. (2012) Dengue. N. Engl. J. Med 366, 1423–1432
- Sudiro T.M., Zivny J., Ishiko H., Green S., Vaughn D.W., Kalayanarooj S. and et al (2001) Analysis of plasma viral RNA levels during acute

- dengue virus infection using quantitative competitor reverse transcription- polymerase chain reaction. *J Med Virol* 63:29–34.
- Vairo F., Nicastri E., Yussuf S.M., C S.A., Mwanakheir M., Mahmoud A.A. and et al (2014) IgG Against Dengue Virus in Healthy Blood Donors, Zanzibar, Tanzania. *Emerging Infectious Diseases* 20:465-468.
- WHO (1995) Report of the Consultation on: Key Issues in dengue vector control towards the operationalization of a global strategy. WHO CTD/FIL (DEN)/IC/96.1: Geneva.
- WHO (2009) Dengue: Guidelines for Diagnosis,

- Treatment, Prevention and Control WHO/ HTM/NTD/DEN.
- WHO (2012) Dengue and Severe Dengue WHO Media Centre.
- Wilder-Smith A., Foo W., Earnest A., Sremulanathan S. and Paton N.I. (2004) Seroepidemiology of dengue in the adult population of Singapore. *Trop Med Int Health* 9:305–8
- Wilder-Smith A. and Gubler D.J. (2008) Geographic expansion of dengue: the impact of international travel. *Med Clin North Am* 92:1377–1390
- Wilder-Smith A. and Schwartz E. (2005) Dengue in



